130 related articles for article (PubMed ID: 22701752)
1. Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis.
Priotto G; Chappuis F; Bastard M; Flevaud L; Etard JF
PLoS Negl Trop Dis; 2012; 6(6):e1662. PubMed ID: 22701752
[TBL] [Abstract][Full Text] [Related]
2. How to shorten patient follow-up after treatment for Trypanosoma brucei gambiense sleeping sickness.
Mumba Ngoyi D; Lejon V; Pyana P; Boelaert M; Ilunga M; Menten J; Mulunda JP; Van Nieuwenhove S; Muyembe Tamfum JJ; Büscher P
J Infect Dis; 2010 Feb; 201(3):453-63. PubMed ID: 20047500
[TBL] [Abstract][Full Text] [Related]
3. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis.
Lejon V; Roger I; Mumba Ngoyi D; Menten J; Robays J; N'siesi FX; Bisser S; Boelaert M; Büscher P
Clin Infect Dis; 2008 Jul; 47(1):15-22. PubMed ID: 18494605
[TBL] [Abstract][Full Text] [Related]
4. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
[TBL] [Abstract][Full Text] [Related]
5. Isolation of Trypanosoma brucei gambiense from cured and relapsed sleeping sickness patients and adaptation to laboratory mice.
Pyana PP; Ngay Lukusa I; Mumba Ngoyi D; Van Reet N; Kaiser M; Karhemere Bin Shamamba S; Büscher P
PLoS Negl Trop Dis; 2011 Apr; 5(4):e1025. PubMed ID: 21526217
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis.
Checchi F; Chappuis F; Karunakara U; Priotto G; Chandramohan D
PLoS Negl Trop Dis; 2011 Jul; 5(7):e1233. PubMed ID: 21750745
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis.
Doua F; Miezan TW; Sanon Singaro JR; Boa Yapo F; Baltz T
Am J Trop Med Hyg; 1996 Dec; 55(6):586-8. PubMed ID: 9025682
[TBL] [Abstract][Full Text] [Related]
8. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.
Kande Betu Ku Mesu V; Mutombo Kalonji W; Bardonneau C; Valverde Mordt O; Ngolo Tete D; Blesson S; Simon F; Delhomme S; Bernhard S; Mahenzi Mbembo H; Mpia Moke C; Lumeya Vuvu S; Mudji E'kitiak J; Akwaso Masa F; Mukendi Ilunga M; Mpoyi Muamba Nzambi D; Mayala Malu T; Kapongo Tshilumbwa S; Botalema Bolengi F; Nkieri Matsho M; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Glob Health; 2021 Jul; 9(7):e999-e1008. PubMed ID: 34143998
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: Report from a field study.
Kuemmerle A; Schmid C; Bernhard S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete DN; Kisala M; Burri C; Blesson S; Valverde Mordt O
PLoS Negl Trop Dis; 2021 Nov; 15(11):e0009903. PubMed ID: 34748572
[TBL] [Abstract][Full Text] [Related]
10. Trypanosoma brucei gambiense Spliced Leader RNA Is a More Specific Marker for Cure of Human African Trypanosomiasis Than T. b. gambiense DNA.
Ilboudo H; Camara O; Ravel S; Bucheton B; Lejon V; Camara M; Kaboré J; Jamonneau V; Deborggraeve S
J Infect Dis; 2015 Dec; 212(12):1996-8. PubMed ID: 26080371
[TBL] [Abstract][Full Text] [Related]
11. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo.
Alirol E; Schrumpf D; Amici Heradi J; Riedel A; de Patoul C; Quere M; Chappuis F
Clin Infect Dis; 2013 Jan; 56(2):195-203. PubMed ID: 23074318
[TBL] [Abstract][Full Text] [Related]
12. Neopterin is a cerebrospinal fluid marker for treatment outcome evaluation in patients affected by Trypanosoma brucei gambiense sleeping sickness.
Tiberti N; Lejon V; Hainard A; Courtioux B; Robin X; Turck N; Kristensson K; Matovu E; Enyaru JC; Mumba Ngoyi D; Krishna S; Bisser S; Ndung'u JM; Büscher P; Sanchez JC
PLoS Negl Trop Dis; 2013; 7(2):e2088. PubMed ID: 23469311
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Betu Kumeso VK; Kalonji WM; Rembry S; Valverde Mordt O; Ngolo Tete D; Prêtre A; Delhomme S; Ilunga Wa Kyhi M; Camara M; Catusse J; Schneitter S; Nusbaumer M; Mwamba Miaka E; Mahenzi Mbembo H; Makaya Mayawula J; Layba Camara M; Akwaso Massa F; Kaninda Badibabi L; Kasongo Bonama A; Kavunga Lukula P; Mutanda Kalonji S; Mariero Philemon P; Mokilifi Nganyonyi R; Embana Mankiara H; Asuka Akongo Nguba A; Kobo Muanza V; Mulenge Nasandhel E; Fifi Nzeza Bambuwu A; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet Infect Dis; 2023 Apr; 23(4):463-470. PubMed ID: 36460027
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo.
Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U
Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357
[TBL] [Abstract][Full Text] [Related]
15. Comparison of operational criteria for treatment outcome in gambiense human African trypanosomiasis.
Mumba Ngoyi D; Lejon V; N'Siesi FX; Boelaert M; Büscher P
Trop Med Int Health; 2009 Apr; 14(4):438-44. PubMed ID: 19228348
[TBL] [Abstract][Full Text] [Related]
16. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo.
Priotto G; Kasparian S; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Karunakara U
Clin Infect Dis; 2007 Dec; 45(11):1435-42. PubMed ID: 17990225
[TBL] [Abstract][Full Text] [Related]
17. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.
Mesu VKBK; Kalonji WM; Bardonneau C; Mordt OV; Blesson S; Simon F; Delhomme S; Bernhard S; Kuziena W; Lubaki JF; Vuvu SL; Ngima PN; Mbembo HM; Ilunga M; Bonama AK; Heradi JA; Solomo JLL; Mandula G; Badibabi LK; Dama FR; Lukula PK; Tete DN; Lumbala C; Scherrer B; Strub-Wourgaft N; Tarral A
Lancet; 2018 Jan; 391(10116):144-154. PubMed ID: 29113731
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes.
Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F
Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness.
Tiberti N; Hainard A; Lejon V; Courtioux B; Matovu E; Enyaru JC; Robin X; Turck N; Kristensson K; Ngoyi DM; Vatunga GM; Krishna S; Büscher P; Bisser S; Ndung'u JM; Sanchez JC
PLoS One; 2012; 7(7):e40909. PubMed ID: 22815865
[TBL] [Abstract][Full Text] [Related]
20. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
Schmid C; Kuemmerle A; Blum J; Ghabri S; Kande V; Mutombo W; Ilunga M; Lumpungu I; Mutanda S; Nganzobo P; Tete D; Mubwa N; Kisala M; Blesson S; Mordt OV
PLoS Negl Trop Dis; 2012; 6(11):e1920. PubMed ID: 23209861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
